Get started
Author

Daryl Barnett

Observed name: D Barnett
OpenAlex ID: A5065020945
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®
2008 · Robert W. Robey, Suneet Shukla, et al. · Biochemical Pharmacology · 158
Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma
2015 · Marilù Fanelli, Claudia Maria Hattinger, et al. · Current Cancer Drug Targets · 57
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1® in Combination With Paclitaxel in Solid Tumors
2012 · Ronan J. Kelly, Robert W. Robey, et al. · The Oncologist · 43
PDF
A Phase I and Pharmacokinetic Study of CBT-1 as a Multidrug Resistance Modulator in the Treatment of Patients with Advanced Cancer
1998 · Robert K. Oldham, William K. Reid, et al. · Cancer Biotherapy and Radiopharmaceuticals · 18
Preclinical toxicology of ifosfamide.
1982 · D Barnett · PubMed · 17
Phase I Study of CBT-1™ and Taxol® in Patients with Taxol® Resistant Cancers
2000 · Robert K. Oldham, William K. Reid, et al. · Cancer Biotherapy and Radiopharmaceuticals · 14
CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin.
2019 · Gregory Michael Cote, Sant P. Chawla, et al. · Journal of Clinical Oncology · 3
Works count: 7
Citation count: 310
H-index: 6
I10-index: 6
Year
Topic
Type